ABSTRACT -Organophosphates (OPs) are important toxic compounds commonly used for a variety of purposes in agriculture, industry and household settings. It has been well established that the main mechanism of acute toxic action of OP is the inhibition of acetylcholinesterase (AChE). However, we observed long term deficit after acute subcutaneous exposure to Chlorpyrifos (CPF) even when AChE activity is restored. In fact, besides AChE inhibition, non-AChE targets have also been proposed as an alternative mechanism involved in the acute lethal action and side effects of short or long-term exposure. In this context, our main aim in this research was to establish a dose-response curve of Acylpeptide hydrolase (APH) and AChE regional brain activity after acute CPF administration that could explain these long term effects observed in the literature. Moreover, since available data suggest that long term effects of OPs exposure could involve neuronal cell death, our second aim was to evaluate, assessing by Fluoro-Jade B (FJB) staining, whether CPF produces induced cell death. Our results show that an acute exposure to 250 mg/kg CPF does not induce neuronal death as measured by FJB but produces highest AChE regional brain inhibition after administration. In addition, APH seems to be more sensitive than AChE to CPF exposure because after 31 days of exposure, complete recovery was seen only for APH activity at Frontal Cortex, Cerebellum and Brain Stem.
INTRODUCTION
Organophosphates (OPs) are important toxic compounds commonly used for a variety of purposes in agriculture, industry and household settings (Maroni et al., 2000; Pope, 1999) . It has been well established that the main mechanism of acute toxic action of OPs is AChE inhibition (Lotti, 2001) . It is generally considered that an extensive inhibition of this enzyme (> 50-60%) results in acute cholinergic toxicity (Pope, 1999) . Nevertheless, several studies have shown a higher enzyme inhibition without signs of acute cholinergic toxicity (McDaniel and Moser, 2004) . Moreover, there are numerous studies in both humans (Fiedler et al., 1997; Kaplan et al., 1993; Roldán-Tapia et al., 2005; Steenland et al., 1994; Stephens et al., 1995) and animals following acute (Bushnell et al., 1993 (Bushnell et al., , 2001 López-Crespo et al., 2009; Sánchez-Amate et al., 2001 or after chronic or repeated exposure to OPs (Castillo et al., 2002; Cohn and McPhail, 1997; Kassa et al., 2001; Llorens et al., 1993; Prendergast et al., 1997 Prendergast et al., , 1998 showing long-term effects months or years after the exposure when AChE activity is restored (for review see Costa, 2006) . Accordingly, besides AChE inhibition, non-AChE targets have also been proposed as an alternative mechanism involved in the acute lethal action and side effects of short or longDose-dependent regional brain acetylcholinesterase and acylpeptide hydrolase inhibition without cell death after chlorpyrifos administration term exposure to OPs (Casida and Quistad, 2004) . Among these new targets, a serine esterase, called acylpeptide hydrolase (APH), was proposed in 2000 as both a toxicological and pharmacological target for OPs (Richards et al., 2000) . In fact, recent approaches in the field of biomarkers of human exposure to OPs apart from considering the inhibition of cholinesteraseas (ChE), the standard biomarker, also include the level of APH activity, among others (Kim et al., 2010; Marsillach et al., 2011) . Moreover, recent research have indicated the involvement of mechanisms such as oxidative stress (López-Granero et al., 2013; Qiao et al., 2005; Zaja-Milatovic et al., 2009) , cytokine system (Carvajal et al., 2005; López-Grancha et al., 2006) , or AChE expression as read-through splice variant (AChE-R) (López-Granero et al., 2013; Meshorer et al., 2002; Meshorer and Soreq, 2006) among the neurotoxic effects of OPs. Our group works on an animal model assessing the persistent consequences following OPs exposure after acute subcutaneous administration of Chlorpyrifos (CPF) in adult Wistar rats. In our previous researches, we observed that CPF-induced inhibition of AChE activity beyond 80% was not associated with the typical signs of toxicity, except body weight reduction and light hypothermia (López-Crespo et al., 2007; Moreno et al., 2008; Sánchez-Amate et al., 2001 . Several studies have reported about the relation between cognitive impairments and short-term OPs intoxication (Bushnell and Moser, 2006; Bushnell et al., 2001; López-Crespo et al., 2007; López-Granero et al., 2013) . Moreover, we found long-term effects in memory and impulsive behaviour (Cañadas et al., 2005; Cardona et al., 2006 Cardona et al., , 2011 Sánchez-Santed et al., 2004) in absence of this toxicity and when the AChE activity is restored (Pope et al., 1992) . These previous results seem to point to other mechanism, besides AChE inihibion, could explain these long term squeals. Therefore, the latest interest of our group is to evaluate the role of other enzymes and mechanism in the role of CPF toxicity in relationship with AChE inhibition. In fact, we have recently assessed the sensitivity of AChE forms (soluble and particulate) as well as the APH to different OPs in whole brain. Regarding to CPF, our results showed that both AChE forms were highly inhibited without differences between them at 3 hr, 24 and 48 hr after acute administration. Interestingly, CPF inhibition of APH was not noted in whole brain, although this enzyme was highly inhibited after Diisopropylphosphorofluoridate (DFP) exposure 1h, 3h and 48h following exposure (López-Granero et al., 2013) .
In this context, our aim in this research was to continue evaluating the putative targets (ChE and APH) that could explain these long term effects observed in the literature. In order to accomplish this, we first evaluated if APH inhibition plays a more significant role in CPF toxicity if we increase the scope of analysis as well as the doses. So in our first experiment evaluated the role of APH inhibition in the CPF toxicity establishing a dose-response curve of APH regional brain activity after acute CPF administration. As control we measured the inhibitory effect of CPF on AChE activity in the same brain areas. Most research in the field measured AChE activity in the whole brain or restricted brain regions (Betancourt et al., 2007; Karanth et al., 2006; Lee et al., 2011) . Thus, there are few studies that have investigated the consequences of OPs on AChE regional activity (Perrier et al., 2005) , although the relevance of brain regional activity for cholinergic and noncholinergic parameters involved as in mechanisms of toxicity of OPs has been pointed (Gupta, 2004) .
Finally, since available data suggest that long term effects of OPs exposure could involve neuronal cell death (Carlson et al., 2000; Damodaran et al., 2006) , our second aim was to evaluate whether CPF produces induced cell death under our exposure conditions. For this purpose animals were injected with the highest dose of CPF (250 mg/kg), and Fluoro-Jade B (FJB) staining, a fluorescent dye that has been used with other toxic compounds (Boadas-Vaello et al., 2005; Schumed and Hopkins, 2000; Seoane et al., 2005; Soler-Martín et al., 2010) , was used to visualize dying cells.
MATERIALS AND METHODS

Animals
For all experiments we used 3-month-old male Wistar rats that were purchased from the Charles River Laboratories (Spain). The rats were housed in groups of three in an environmentally controlled room (22ºC with 8:00 hr/ 20:00 hr light/dark cycle). Food and water were continuously available. Animals were provided 15 days of habituation to the local conditions before experimentation began. All procedures were performed in accordance with Spanish Royal Decree 1201/2005 on the protection of experimental animals, and with the European Communities Council Directive (86/609/EEC). The number of animals used in each study is indicated in the "Procedure" section (see below). istration were chosen based on previous data of our laboratory that showed predictably profound and prolonged cholinesterase inhibition, as well as long term cognitive and emotional effects after the higher dose exposure without acute toxicity (Cañadas et al., 2005; Cardona et al., 2006 Cardona et al., , 2011 . Others (Levin et al., 2010; Lin et al., 2012; Pope et al., 1991) have worked with subcutaneous exposure for a number of years, and Pope et al. (1991) determined the subcutaneous Maximal Tolerated Doses of CPF to be 279 mg/kg, causing extensive inhibition of ChE activity in brain (> 78% of inhibition), plasma (> 80% of inhibition) and erythrocytes (> 80% of inhibition) in adults rats.
Apparatus
AChE activity determination: For biochemical assays, a DU 530 Beckman spectrophotometer was used.
Histology: Leica VT1000M vibrating blade microtome and Nikon E800 fluorescence microscope.
Procedure
Experiment 1: AChE and APH activity in regional brain Experimental design: Four groups of rats were used and given CPF 50 (n = 12), CPF 125 (n = 12), CPF 250 (n = 12) or VHC (n = 12). Acute toxicity was assessed at 48 hr after treatment using a modified version (Sánchez-Amate et al., 2001) of the functional observational battery of McDaniell and Moser (1993) .
Three animals of each group were euthanized at 2, 7, 14 and 31 days after CPF administration. Brains were quickly removed, frozen, and stored at -80ºC until preparation (Moreno et al., 2008) . For brain tissue preparation, the samples were thawed, and the striatum (S), hippocampus (HC), frontal cortex (FC), amygdale (AMY), cerebellum (CR) and brainstem (BS) were dissected, weighed, and homogenized in a buffer containing: 50 nM Tris-HCl, 1M NaCl, 50 mM MgCl 2 , 10 μg/ml aprotinine, 2 μg/ml leupeptine and 1% triton X-100, pH 8.0 4ºC. The homogenate was centrifuged at 15,000 x g for 20 min. The pellet was discarded and the supernatant was kept for AChE and APH assay.
Determination of AChE activity in regional brain: Acetylcholinesterase activity was determined spectrophotometrically by adaptation of the Ellman method (Ellman et al., 1961) (Wilson and Henderson, 2007) using acetylthiocholine iodide (9 μl; final concentration = 0.5 mM) as substrate for AChE. The sample (10 μl) was mixed with 5,5´-dithiobis-2-nitrobenzoic acid (DTNB, 60 μl; final concentration = 0.33 mM), 206 μl of 0.1 M Na-phosphate buffer, pH 8. Control measurement were performed by adding tetraisopropyl pyrophosphoramide (ISO-OMPA, 15 μl; final concentration = 50 μM a specific inhibitor of BuChE). Enzyme activity was calculated relative to protein concentration by the Bradford method (Bradford, 1976 ) and using Glutathione (1 mM) standard curve to calculate ChE activity (slope: 0.03470 M -1 /cm) (Wilson and Henderson, 2007) .
Determination of APH activity in brain: Triton X-100 at 1% (225 μl) was added to the homogenate and incubated in ice-water for 30 min. Next, the sample was centrifuged at 15,000 x g and the supernatant was used for analysis of APH activity by adaptation of the Perrier method (Perrier et al., 2002) . APH activity was determined spectrophotometrically with N-acetyl-alanyl-p-nitroaniline (AANA, 6 μl; final concentration = 1 nmol) as substrate. Briefly, the sample was mixed with 292 μl of 0.2 M TrisHCl buffer pH 7.4 (prepared with 1 mM 1.4-dithio-DLthreitol). The reaction was initiated by dissolving 6 μl of 0.2 M AANA dissolved in dimethylsulfoxide (final concentration 4 mM). The enzyme activity was calculated relative to protein concentration by the Bradford method (Bradford, 1976 ) with a p-nitroaniline (1 mM) standard curve to calculate APH activity (slope: 0.00790 M-1/cm).
Experiment 2: Neuronal death by Fluoro-Jade B staining
Experimental design: Two groups of rats were treated with VHC (n = 4) or CPF 250 (n = 8). Two CPF and one VHC animals were examined for presence of neuronal death at 3, 7, 14 and 30 days after treatment.
Histology: Rats were anaesthetized with ketamine (50 mg/kg, i.p.) and transcardially perfused with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Brain and spinal cord tissues were removed from the perfusionfixed animals and immersed in the same fixative at 4°C for 1-4 days. To examine all brain regions, the whole brain as well as one slice sample from the cervical region of the spinal cord were cut in transverse sections (50 μm) using a Leica VT1000M vibrating blade microtome. Every third section was dried on a microscopy slide for subsequent staining with Fluoro-Jade B (Chemicon International (Temecula, CA, USA), a fluorescent dye that specifically labels degenerating neurons (Schmued and Hopkins, 2000) . Labelled neurons were identified by comparison of the Fluoro-Jade B stained sections with the appearance of the corresponding structures in the normal rat brain, according to the atlases by Paxinos and Watson, (1998) . Piriform cortex sections from rats treated with transcrotononitrile were used as positive controls (BoadasVaello et al., 2005) .
Data analysis
Statements of statistical significance were based on repeated measures ANOVA for the AChE-APH activity, with Dose (VHC, CPF 50 , CPF 125 and CPF 250 ) as betweensubject factor, and Time (2, 7, 14, 31 days) as within-subject factor. FOB parameters were analyzed by repeated measures ANOVA, using Dose (VHC, CPF 50 , CPF 125 and CPF 250 ) as between-subject factor and Hours (day injection and 48 hr) as within-subject factor. All analyses were performed using the Statistica software package. The Newman-Keuls test was used for post-hoc analysis. The accepted level of significance for all tests was P 0.05. Additionally to the statistical significance levels, η2 (etasquared) was calculated owing to the reduce number of the subjects. This is an indicator that provides an estimate of the magnitude of the effects and is independent of the sample size (Rosnow et al., 2000) .
RESULTS
Toxicity evaluation
As expected according to the literature (Cañadas et al., 2005; Cardona et al., 2006 Cardona et al., , 2011 López-Granero et al., 2013; Pope et al., 1992; Sánchez-Santed et al., 2004) , no signs of acute toxicity were observed after CPF administration (data not shown), except for a reduction of body weight for the doses of CPF 125 and CPF 250 (F (3,44) = 11.33; p < 0.05).
Experiment 1
Before comparing the CPF doses we evaluated the different basal activity in the brain regions. Accordingly, a repeated measure ANOVA for each enzyme was made only for VHC group (n = 12) with the regional brain activity (amygdale, frontal cortex, striatum, hippocampus, cerebellum and brainstem) as within-subject factor. The ANOVA showed a significant Region effect in both enzymes (on AChE value (F(5,55) = 44,1206; p < 0.05) and APH value (F(5,55) = 21,8167; p < 0.05)). Striatum showed the higher AChE activity (22.434340 μmmol/mg/ min) while the lower AChE activity was found in cerebellum (4.1568 μmmol/mg/min). However, the same region showed the higher APH activity (15.3678 μmmol/mg/min) whereas amygdale was the region with the lower APH activity (4.6691 μmmol/mg/min). These results can be seen in the Fig. 1 . Fig. 2 shows the degree of AChE (left) and APH (right) regional brain activity at several temporal moments after acute exposure to CPF at doses expressed as percent respect to VHC. In general a significant dose-response curve (Dose effect) was found for both enzymes and at every region analysed. However, the rate of recovery shown for both enzymes in most of the regions (Dose x Time interaction) was different. That is, after 31 days of exposure, complete recovery was seen only for APH activity at Frontal Cortex, Cerebellum and Brain Stem (Fig. 2) .
In Frontal Cortex the ANOVA showed a significant Dose effect for both variables (AChE (F(3,8) and CPF 250 in the AChE case, but for the APH case the post-hoc revealed significant for all the doses respect to VHC (p < 0.05); also CPF 250 showed higher inhibition when compared with CPF 50 and CPF 125 . Moreover, the Dose x Time interaction in APH value was also significant (F(9,24) = 2,5310; p < 0.05, η2 = 0.49) and further analysis at each time point showed larger inhibition for the higher dose at day 2 (p < 0.05), and a complete recovery one month later for all the doses. In Hippocampus the ANOVA again showed a significant Dose effect for both enzymes (AChE: (F(3,8) = 106,8867; p < 0.05, η2 = 0.98) and APH: (F(3,8) = 21,3781; p < 0.05, η2 = 0.89)) that post-hoc revealed significant for all the doses (p < 0.05) in AChE analysis but in APH analysis showed no differences between CPF doses. Accordingly, APH recovery, although not complete at 31 days, was similar for the three doses (F(9,24) = 1,8128; p < 0.05). The Dose x Time interaction in AChE activity resulted significant (F(9,24) = 3,1983; p < 0.05, η2 = 0.55). The post-hoc showed significant differences between all doses except CPF 125 and CPF 250 at day 2 and 14. The post hoc undertaken at days 7 and 31 after treatments showed that all the doses had differences with respect to VHC, and also CPF 250 has significant differences with all the doses. Thus recovery occurs, although inhibition is still significant after 31 days, being higher for 250 mg/kg.
The ANOVA carried out in Amygdale showed a significant Dose effect (on AChE value (F(3,8) = 43,9390; p < 0.05, η2 = 0.94) and APH value (F(3,8) = 16,2268; p < 0.05, η2 = 0.86)) but no the interaction. Post-hoc analysis in amygdale indicated that all doses are different among them (p < 0.
05) in both measures
In Striatum the ANOVA showed a significant Dose effect for both enzymes (AChE: (F(3,8) = 32,2276; p < 0.05, η2 = 0.92), APH: (F(3,8) = 5,8952; p < 0.05, η2 = 0.69)). The post-hoc in AChE analysis was significant for all the doses (p < 0.05) except CPF 125 and CPF 250 ; the post-hoc in APH activity showed significant differences between CPF 125 and CPF 250 respect to VHC. Moreover, the Dose x Time interaction in AChE value was also significant (F(9,24) = 2,7705; p < 0.05, η2 = 0.51) and the post-hoc showed significant differences between all doses at day 2; at day 7 and day 14 the differences between CPF 125 and CPF 250 disappeared; and 31 days after administration, only CPF 250 showed significant differences with respect to the rest of doses.
In Cerebellum the ANOVA showed a significant Dose effect for both enzymes (AChE: (F(3,8) = 33,7349; p < 0.05, η2 = 0.93) and APH: (F(3,8) = 48,893; p < 0.05, η2 = 0.95)); post-hoc in AChE analysis revealed that all the doses inhibited the enzyme as compared with VHC (p < 0.05), while CPF 250 showed the highest inhibition (p < 0.05). Post-hoc in APH analysis revealed no significant differences between CPF 50 and CPF 125 (p < 0.05). In AChE measure the Dose x Time interaction also resulted significant (F(9,24) = 4,2557; p < 0.05, η2 = 0.62). The post hoc revealed different rates of activity recovery: thus, significant differences between all the doses respect to the VHC at days 2 and 7 were found, while at day 14 only the highest doses showed differences with VHC; at day 31 no significant differences were observed. In APH measure the Dose x Time interaction resulted almost significant (F(9,24) = 2,232; p = 0.056, η2 = 0.46).
Finally, in Brainstem the ANOVA again showed a significant Dose effect in both measures (AChE: (F(3,8) = 68,061; p < 0.05, η2 = 0.96) and APH: (F(3,8) = 9,4473; p < 0.05, η2 = 0.78)); post-hoc in AChE analyse revealed significant for all the doses (p < 0.05), and post-hoc in APH analyse revealed significant for all the doses respect to the VHC (p < 0.05). In addition, the Dose x Time interaction resulted significant in both (AChE: (F(9,24) = 3,212; p < 0.05, η2 = 0.55) and APH: (F(9,24) = 2,2842; p = 0.05, η2 = 0.46)). The post hoc in AChE analysis revealed significant differences between all doses respect to the VHC at day 2. At days 7 and 14, only the higher doses showed differences with VHC; at day 31 only significant differences between CPF 250 and VHC were observed. The post hoc in APH analysis revealed significant differences between all the doses respect to the VHC at days 2, 7 and 14. At days 7 and 14, CPF 250 and CPF 50 also showed significant differences.
Experiment 2: Neuronal death by Fluoro-Jade B staining
The fluoro-jade B staining protocol used was able to reveal dying neurons, as demonstrated by the labelling found in the piriform cortex samples from rats treated with trans-crotononitrile (Boadas-Vaello et al., 2005) used as positive controls. However, no dying neurons were found in animals administered with CPF 250 in any brain region at either 3, 7, 10 or 30 days after exposure (data not shown).
Due to the absence of staining with the highest dose, no animals were treated for Fluoro-Jade B labelling at lower doses.
DISCUSSION
The main purpose of this research was to evaluate the pattern of brain distribution of the enzyme APH compared to AChE and their recovery dynamics after being inhibited by different doses of CPF. For this, we obtained a pro- file of the distribution of AChE and APH activities in different brain structures and then we studied the inhibitory effect of a unique administration of several dose of CPF on both enzymes establishing a dose-response curve of AChE and APH regional brain activity. Our results show that subcutaneous injections of CPF produce a strong inhibition of both enzymes in all the brain regions evaluated and, as expected, without the typical signs of acute toxicity, proving that the dose used was lower than the Maximum Tolerated Dose (Pope et al., 1992) . Both dose effect and time-course of the regional inhibition were different for each of the enzymes tested. AChE showed a dose-dependent effect in most of the regions assessed, especially for the higher doses. This effect was clearly observed in amygdale, hippocampus and brainstem. However, both in frontal cortex and striatum, at the peak of inhibition between 2 and 7 days after administration, the two higher doses achieved similar levels of AChE activity reduction. Similar results have previously been reported in striatum following acute sc CPF administration (Karanth et al., 2006) . In this report, using in vivo microdialysis, authors found that the levels of ACh in rat striatum are higher at 4 and 7 days after dosing (84, 156 and 279 mg/kg of CPF, s.c.) than at day 1. When assessed up to 7 days after administration ChE inhibition reached an apparent ceiling effect at doses above 100 mg/kg. Our results show that this ceiling effect can be extended to frontal cortex but not to the rest of the evaluated regions or for periods longer than two weeks post-administration. In fact, 31 days after administration 250 mg/kg of CPF was the only dose that maintained some degree of inhibition of AChE activity, whereas 125 mg/kg CPF reached the level of activity of the subjects treated with vehicle. In contrast, APH activity was less reduced in comparison with the AChE activity. Furthermore, there was relatively low dose-related effect, with the exception of frontal cortex and amygdala. The ceiling effect with subcutaneous CPF was reached at 50 mg/kg in hippocampus, cerebellum and brainstem and 125 mg/kg in striatum.
In terms of recovery of enzyme activity, the time-course for AChE activity showed clear differences depending on the area analyzed. It is well known that CPF reduces brain AChE activity for a long period and it is restored around ten weeks after treatment (Cardona et al., 2011; Pope et al., 1992) . However, such a brain AChE activity recuperation seems to be region-dependent. In fact, in striatum, brainstem and cerebellum activity levels tend to be similar to that of control subjects between 2 and 4 weeks post-treatment. The only exception to this recovery was observed with the higher dose of CPF in striatum and brainstem. In these areas, AChE inhibition persisted beyond one month after 250 mg/kg of CPF administration. In contrast, in cerebellum AChE activity almost fully recovered 14 days after treatment, and none of the doses produced a significant inhibition of the AChE at 31 days of treatment. Nevertheless, the time-course of the activity recuperation is quite different in amygdale, frontal cortex and hippocampus. In this last group of regions AChE activity was still inhibited 31 days after the exposure due to a low degree of recovery. For example, in hippocampus all the doses produced an elevated inhibition even 31 days after treatment. Thus, the long period for wholebrain AChE activity recovery reported in the literature following acute sc CPF administration appears to be associated with the longer duration of the inhibition in these specific brain areas. Moreover, these differences in the recovery of the activity among areas could help to explain the different time-course of behavioral effects of a single acute dose of CPF observed previously. That is, anxiogenic-like effect at day 2 as well as the anxiolytic-like effect at 5 days after CPF acute exposure (López-Crespo et al., 2007 Sánchez-Amate et al., 2001) could be due to the pattern of recovery of AChE inhibition and its simultaneous actions on different neurochemical systems Accordingly, Moreno et al. (2008) found different patterns of monoaminergic activity changes over time on different brain structures after CPF treatment on adult rats. The same high dose of CPF that we have employed in the present research, produced changes in dopamine metabolism after 2 days and changes in serotonin turnover 7 and 15 days after its administration on the striatum but not on the nucleus accumbens.
In contrast, this region-dependent recovery phenomenon was not observed in relation to APH activity. With the exception of both, brainstem and cerebellum, none of the regions tested showed recovery of enzyme activity with the lapse of weeks. Only brainstem and cerebellum show time effect and, in both cases, the activity of the enzyme is recovered before 31 days post-treatment. Thus, although the maximum level of inhibition observed for this enzyme is inferior to that seen for AChE, APH appears to be more sensitive to the exposure to CPF. As mentioned above, the maximum degree of inhibition in each region was observed with doses as low as 50 mg/kg (except in amygdala and frontal cortex). Besides this, APH activity takes longer to recover in most regions examined. According to previous (López- Granero et al., 2013) and present results APH seems not to be more sensitive to CPF than AChE during the first 48 hr, but after that time it increase its sensitivity and takes longer to recover. Similar results, although with a greater degree of inhibition of APH with respect to AChE, have been previously described for other organophosphorus compounds such as dichlorvos (Olmos et al., 2009) and DFP (Richard et al., 2000) .
Returning to AChE inhibition, the literature indicated that although regions with lower levels of AChE could show greater inhibition, depending of the OPs used and on the time of evaluation (Gupta, 2004) . In contrast, Karanth et al. (2006) have suggested that regions with higher cholinesterase specific activity, such as striatum, would take longer to recover normal activity following CPF exposure. However, we have found a strong inhibition in all the zones analyzed during the peak of inhibition, regardless of the densities of cholinesterases in the tissues. Moreover, in our research, under our conditions, the time course of enzyme recuperation appears to be independent of the baseline of AChE activity. For example, we have described similar recovery patterns in cerebellum and striatum, regions with low and high AChE activity, respectively (Hammond et al., 1996) .
It is noteworthy that the highest dose of CPF (250 mg/ kg) is the only dose that caused AChE inhibition in striatum after 31 days of CPF exposure. Moreover, regions such as frontal cortex, hippocampus and amygdale are still inhibited after 31 days of exposure. Previously (Moreno et al., 2008) we found similar results in striatum and nucleus accumbens after acute exposure of 250 mg/kg of CPF. Other researchers found that CPF administration reduces AChE activity in hippocampus (Levin et al., 2002; Prendergast et al., 2007; Slotkin et al., 2001) . These regions are involved in impulsive behaviour and spatial memory (D'Hooge and DeDeyn, 2001; Winstanley et al., 2006) . Therefore, the long-term effects observed in our lab after CPF 250 administration, such as the increase in impulsivity (Cardona et al., 2006 (Cardona et al., , 2011 and the spatial memory deficit (Cañadas et al., 2005; Sánchez-Santed et al., 2004) could be due to consequences of this longer AChE inhibition in these areas.
In our second experiment our aim was to detect, for first time, neuronal death in vivo after administration of a dose of CPF that produces the highest AChE inhibition and we did not find it. Fluoro-Jade fluorochromes label neurons at a late stage in degeneration, at a time when cell loss occurs, and are a marker of neuronal death irrespective of the type of cell death (apoptosis or necrosis) involved (Krinke et al., 2001; Rocha et al., 2004; Schumed and Hopkins, 2000; Seoane et al., 2005) . The labeling of the positive control samples from rats treated with trans-crotononitrile (Boadas-Vaello et al., 2005) demonstrated that the staining process was performed adequately. We concluded that an acute sc dose of CPF does not produce neuronal death, at least within one month after acute exposure.
Neuronal death in vivo has been usually documented after administration of OPs that produce severe acute signs of toxicity (e.g. convulsion and hypoxia), such as soman (Collombet et al., 2006; Myhrer et al., 2005) . Jortner et al. (2005) administered tri-ortho-tolyl phosphate (TOTP) and CPF, individually and in combination, over a 63-day period. TOTP was administered in 14 gavage doses of 75, 150 or 300 mg/kg, and CPF was given in two 60 mg/kg sc exposures. The major neuropathologic change was the presence of axonal degeneration progressing to myelinated fiber degeneration, seen only in animals treated with the higher doses of TOTP, at the same time that the neurotoxic esterase enzyme (NTE) in hippocampal tissue was inhibited. Moreover, FJB staining has been effective to detect neuronal death in chickens after administration of triphenyl phosphite (TPPI), an OP that also produces OPIDN (Carlson and Ehrich, 2004) . Therefore, neuronal death in vivo is usually documented after administration of OPs that produce severe acute signs of toxicity, such as convulsion and hypoxia. Consequently, the absence of neuronal death could be related to the lack of signs of acute toxicity observed after the CPF 250 administration. Our enzymatic data lead us to conclude that high AChE inhibition after acute CPF exposure is not directly related to cell death.
Finally, our research shows that an acute exposure to 250 mg/kg CPF does not induce neuronal death as measured by FJB but produces higher AChE regional brain inhibition after administration. In addition, APH seems to be more sensitive than AChE to CPF exposure. Therefore, our previous results showing long-term deficit after acute CPF exposure cited above, not could be explained by neuronal death. These deficits could be explained by long term consequences of the higher AChE regional inhibition observed. However, all these data together point to the importance of evaluating other proteins such as MAP-2 (Prendergast et al., 2007; Ruiz-Muñoz et al., 2011) or other neurotransmitters like serotonin or dopamine systems, and some hormones, as potential targets for CPF (Casida et al., 2008; Tait et al., 2009; Venerosi et al., 2008) that explain the long term effects observed and cited above.
